Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano announced the expansion of their Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization for international execution of Study SP-03-B101. This move follows recent regulatory approvals supporting study expansion and marks the transition of the Sapu003 program from an Australia-based clinical effort toward a broader multinational development strategy, including planned expansion into Europe.
SP-03-B101 is an open-label Phase 1b dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors. The company said GCT has already completed key regulatory submissions ahead of schedule and initiated clinical operations, site activation and study management activities. Sapu003 is an intravenous formulation of everolimus developed using Sapu Nano’s Deciparticle platform, which is designed to improve drug delivery and provide more predictable systemic exposure than oral administration while supporting future global registrational studies.
For business and technology leaders, this development signals a strategic pivot toward global clinical execution, potentially accelerating the path to market for a novel cancer therapy. The use of an intravenous formulation could address limitations of oral everolimus, such as variable absorption and food effects, offering more consistent dosing and efficacy. The appointment of a global CRO with experience in multinational trials may reduce timelines and regulatory hurdles, positioning Oncotelic to compete more effectively in the oncology space.
The expansion also highlights the role of advanced drug delivery platforms like Deciparticle in enhancing therapeutic profiles. For the industry, this represents a trend toward reformulating existing drugs to improve outcomes and expand indications. If Sapu003 succeeds in later-stage trials, it could set a precedent for similar approaches with other mTOR inhibitors.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. Beyond internal programs, Oncotelic licenses and co-develops drug candidates through strategic partnerships and joint ventures, including a 45% interest in GMP Bio.
For more details, view the full press release at https://nnw.fm/olX92. The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC.
